A detailed assessment of the current market landscape of drug developers engaged in the development of bispecific antibody therapeutics.
A comprehensive analysis of novel technology platforms that are either currently available or being developed for the generation of bispecific antibody therapeutics.
Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics.